7 Agriculture Stocks to Watch in 2026

Agriculture is not one industry. It is a chain of bottlenecks.

That distinction matters for investors. Buying a farm operator is usually a direct bet on weather, commodity prices, acreage, labor, and input costs. Buying the companies around the farm can be a different proposition entirely. Machinery, seed traits, fertilizer, animal health, crop processing, and protein production all sit near the same end market, but they do not share the same economics.

The useful question is not "will the world need more food?" Of course it will. The useful question is: which companies capture value as the food system becomes more automated, more input-intensive, more data-driven, and more capital constrained?

That is where agriculture stocks get interesting. The sector is cyclical, but the best businesses in the chain can still compound through pricing power, installed bases, regulatory barriers, distribution scale, or hard-to-replicate physical infrastructure.

The seven names below are not interchangeable. Deere is a machinery and precision-technology platform. Zoetis is an animal-health compounder. Corteva and Bayer are crop-science franchises. Nutrien is a fertilizer and retail distribution giant. ADM is food-system infrastructure. Tyson is a protein-cycle recovery story.

Same end market. Very different valuation problems.

The 2026 Agriculture Setup

The agriculture market is being pulled in two directions.

On one side, demand is structurally resilient. Population growth, rising protein consumption, biofuel demand, and pressure to increase yields per acre all support long-term spending across the food system.

On the other side, the economics are messy. Farm income moves in cycles. Fertilizer prices can swing hard. Protein margins can collapse when feed costs or herd dynamics move against producers. Equipment orders are sensitive to farmer cash flow. Weather can turn a clean spreadsheet into comedy in one planting season.

That is why agriculture stocks should not be valued as one basket. A good agriculture screen separates three types of exposure:

1. Productivity enablers: companies that help farms produce more with fewer inputs, such as Deere, Corteva, Bayer, and Zoetis.
2. System infrastructure: companies that move, process, distribute, or supply essential inputs, such as Nutrien and ADM.
3. Commodity-cycle operators: companies whose margins can improve dramatically in the right environment but can also reverse quickly, such as Tyson.

The first group usually deserves a higher-quality lens. The second group needs mid-cycle cash-flow discipline. The third group requires more aggressive scenario testing.

This is where a simple valuation process beats a stock-story process. You do not need a heroic model. You need to understand normalized cash flow, reinvestment needs, cyclicality, and the assumptions the market price already embeds. If that sounds familiar, it is the same discipline behind any serious free cash flow valuation.

1. Deere & Company (DE)

Deere is the cleanest way to invest in the modernization of agriculture, but that does not make it a low-risk stock.

The bull case is obvious. Deere has the brand, dealer network, installed base, and engineering depth to remain central to farm automation. Precision agriculture is not a buzzword when it lowers labor intensity, improves yield, reduces input waste, and gives large farms better control over every pass across the field. Autonomous equipment, connected implements, and software-enabled productivity are the parts of the story investors should care about.

The risk is equally obvious. Deere still sells expensive machines into a cyclical customer base. When crop prices fall or farm income tightens, equipment replacement can be delayed. That makes near-term revenue and margins more volatile than the "agriculture technology platform" label suggests.

The valuation question is whether Deere's higher-margin technology layer can make the business structurally less cyclical over time. If the answer is yes, a premium multiple can be justified. If the answer is no, investors are paying a platform multiple for a machinery cycle.

For Deere, free cash flow quality matters more than the story. A strong cycle can make almost any machinery company look disciplined. The test is whether cash conversion holds up when equipment volumes soften and financing conditions become less friendly.

2. Zoetis (ZTS)

Zoetis is agriculture-adjacent, but it behaves differently from most agriculture stocks.

The company sells vaccines, medicines, diagnostics, and animal-health products across livestock and companion-animal markets. That mix matters. Livestock connects Zoetis to protein production and food supply. Companion animal adds a steadier, higher-margin consumer-health element that can reduce dependence on farm economics.

The moat is not flashy. It is regulatory approvals, veterinarian trust, product breadth, global distribution, and continuous R&D. Those are boring advantages. Boring advantages are often the best kind.

For investors, Zoetis is less about calling the next crop cycle and more about underwriting durable demand, pricing power, and innovation. The company benefits when protein production becomes more efficient and when animal health becomes more professionalized across emerging markets.

The risk is that quality can become over-owned. A great business bought at an undisciplined price is still a bad process. With Zoetis, the key is to stress-test how much growth and margin durability are already priced in.

3. Corteva (CTVA)

Corteva is one of the cleaner pure-play agriculture technology businesses in the public market.

It sells seeds, traits, and crop-protection products. That makes it central to the farmer's productivity equation. Better seed genetics can increase yield. Crop protection can preserve that yield. Biologicals and more targeted inputs can help farmers manage cost, regulation, and soil pressure.

This is not a commodity business in the same way grain handling is a commodity business. Corteva's advantage comes from intellectual property, product development cycles, grower relationships, and distribution. The best version of the company is a recurring innovation engine: new traits, better products, improved mix, and pricing that reflects the value delivered to farmers.

The risk is that agriculture input markets are never smooth. Weather can affect demand. Competitive pricing can pressure crop protection. Regulatory scrutiny can change product economics. Farmers can push back when input costs rise faster than crop revenue.

Corteva belongs in a valuation model that separates revenue growth from margin expansion. If you blur those together, you can double-count the same optimism.

4. Nutrien (NTR)

Nutrien is not a simple fertilizer producer. That is the whole point.

The company has major potash, nitrogen, and phosphate exposure, but it also owns a large agriculture retail network. The production assets give Nutrien leverage to global nutrient demand and pricing cycles. The retail business gives it a direct channel into farmer spending and a more diversified revenue base.

That combination can be attractive, but investors need to be honest about operating leverage. Fertilizer pricing can move sharply. When prices rise, cash flow can surge. When benchmarks normalize, earnings can compress faster than a casual screen suggests.

The right way to look at Nutrien is through mid-cycle economics. Do not value peak fertilizer margins as permanent. Do not treat trough conditions as destiny either. Build a normalized case, then run scenarios around nutrient pricing, volumes, and retail margins.

Nutrien is exactly the kind of stock where a single-point estimate is not enough. Scenario analysis forces the right question: how much of the current equity value depends on fertilizer prices reverting, staying depressed, or overshooting again?

5. Archer-Daniels-Midland (ADM)

ADM is food-system infrastructure hiding in plain sight.

The company originates, transports, stores, processes, and upgrades crops into oils, meal, sweeteners, ethanol, renewable diesel feedstocks, and specialty ingredients. It is not the most exciting agriculture story, which is usually a good sign. Critical infrastructure rarely needs to entertain you.

ADM's earnings are tied to crush spreads, merchandising conditions, crop flows, biofuel economics, and nutrition margins. That makes the business cyclical, but not fragile. The asset network is hard to replicate, and the company sits inside flows the global food system cannot simply route around.

The investment case depends on cash generation through a full cycle. When processing margins are unusually strong, investors should resist annualizing the good times. When margins reset, the question becomes whether ADM can still earn acceptable returns on capital and generate enough free cash flow to support dividends, buybacks, and reinvestment.

ADM is a process stock, not a headline stock. The model should focus on normalized segment profitability, working-capital swings, and how much value sits in the Nutrition business versus the core processing network.

6. Tyson Foods (TSN)

Tyson is the most cyclical name on this list.

The company sells beef, chicken, pork, and prepared foods. Scale gives it real advantages in procurement, processing, distribution, and customer relationships. Prepared Foods can be a steadier profit engine. But the meat businesses remain exposed to livestock supply, feed costs, consumer demand, plant utilization, export markets, and disease pressure.

That is not a reason to ignore Tyson. Cyclical stocks can be attractive when margins are depressed and recovery is underwritten conservatively. But the word "recovery" does a lot of dangerous work in valuation. It can mean operational improvement. It can mean a favorable commodity setup. It can mean investors are just tired of bad news.

Tyson requires a tougher margin-of-safety standard than a steadier compounder. A cheap multiple is not enough if normalized earnings are lower than the market assumes. Before buying a recovery story, investors should define the bear case clearly and decide what discount is required to compensate for execution risk. That discipline is the difference between a valuation and a vibe; it is also why margin of safety matters most in cyclical sectors.

7. Bayer (BAYN)

Bayer is complicated, and complication is usually where lazy valuation gets expensive.

The agriculture business is strategically important. Crop science, seeds, herbicides, pest control, and biotechnology all sit in the productivity layer of the food system. In a cleaner corporate structure, that business would probably get more investor attention as a long-duration agriculture technology franchise.

But Bayer also carries legal and corporate complexity that directly affects valuation. Investors cannot analyze the crop-science business in isolation and pretend the rest of the balance sheet does not exist. The stock can look optically cheap while still deserving a discount if liabilities, governance questions, or capital allocation uncertainty remain unresolved.

That does not make Bayer uninvestable. It makes it a sum-of-the-parts and risk-adjustment problem. The crop-science assets may be valuable, but the equity case depends on what portion of that value actually belongs to shareholders after legal, debt, and portfolio considerations.

For a company like Bayer, the first pass should not be "what multiple is cheap?" It should be "what must go right for the discount to close, and what could permanently absorb the upside?"

How to Value Agriculture Stocks Without Fooling Yourself

Agriculture investing punishes straight-line thinking.

A Deere model that ignores equipment cycles is too clean. A Nutrien model that uses peak fertilizer margins is too generous. A Tyson model that assumes quick margin normalization is too convenient. An ADM model that ignores working capital is incomplete. A Bayer model that ignores legal liabilities is fiction.

Use a different lens for each business model:

• Deere: installed base, technology adoption, equipment replacement cycles, financing exposure, and free cash flow resilience.
• Zoetis: organic growth, pricing power, R&D productivity, regulatory barriers, and valuation premium.
• Corteva: seed mix, crop-protection margins, innovation pipeline, farmer economics, and input-cycle volatility.
• Nutrien: mid-cycle fertilizer prices, potash supply discipline, retail margins, and capital intensity.
• ADM: processing spreads, crop flows, biofuel demand, Nutrition recovery, and working-capital swings.
• Tyson: protein margins, herd cycles, feed costs, plant utilization, and prepared-food stability.
• Bayer: crop-science quality, legal liabilities, balance-sheet constraints, and sum-of-the-parts value.

The mistake is treating "food demand" as a valuation input. Food demand is the backdrop. Cash flow is the asset. Price is the hurdle.

For sector lists like this, I prefer starting with a reverse DCF. It keeps the story honest by asking what future cash flows the current price already requires. Then you can decide whether your thesis is actually differentiated or just borrowed from the market. If you need the broader framework, start with how professional investors structure valuation work before getting lost in ticker-by-ticker narratives.

What Matters Most in 2026

Three themes deserve investor attention.

First, precision agriculture is moving from optional upgrade to operating necessity. Labor scarcity, input inflation, and weather volatility all push farms toward better data, automation, and equipment utilization. Deere is the obvious beneficiary, but seed and input companies also benefit when farms optimize at the acre level.

Second, fertilizer and crop-input economics are normalizing after an unusually volatile period. That creates opportunities and traps. Lower input prices can help farmers, but they can pressure producer margins. Higher nutrient prices can lift earnings, but they can also destroy demand if they move too far too fast.

Third, protein demand remains structurally attractive, but protein producers are still cyclical operators. Zoetis and Tyson both touch the protein theme. They are not the same type of bet. Zoetis sells tools that support animal productivity. Tyson absorbs the margin volatility of producing and processing protein at scale.

That is the broader lesson. The agriculture value chain is connected, but the economics are not identical.

The Bottom Line

Agriculture stocks can give investors exposure to one of the world's essential systems, but essential does not automatically mean attractive.

Deere, Zoetis, Corteva, Nutrien, ADM, Tyson Foods, and Bayer each offer a different version of the agriculture thesis. Some are productivity platforms. Some are infrastructure businesses. Some are cyclical recovery candidates. Some are cheap for reasons that need to be modeled, not hand-waved.

The opportunity in 2026 is not simply finding companies tied to food demand. It is finding the businesses where cash-flow durability, reinvestment economics, and valuation still line up.

That is less exciting than a top-stock list. It is also how serious investors avoid paying for a story that the market has already priced in.